Parkinson's disease from the perspective of general practice;A Parkinson-kór a gyakorló orvosok szemszögébo″l

Lege Artis Medicinae

Volumn 24, Issue 8-9, 2014, Pages 406-414

  Kovács, Norbert ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Deep brain stimulation; Driving; Non pharmacological treatment; Parkinson's disease; Pharmacological treatment

Indexed keywords

EID: 84908012960     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bereczki D. The description of all four cardinal signs of Parkinson's disease in a Hungarian medical text published in 1690. Parkinsonism Relat Disord 2010;16:290-3.
2. Hidasi E. A Parkinson-kór modern szemlélete. Lege Artis Medicinae 2010;20:825-9.
3. Akhtar RS, Stern MB. New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications. Expert Rev Neurother 2012;12:1429-38.
4. Horváth K, Aschermann Z, Komoly S, Kovács A, Kovács N. Tardív szindrómák kezelési leheto″ségei. Psychiatr Hung 2014;29:214-24.
5. Szirmai I. Vascularis vagy "lower body parkinsonizmus". Egy diagnózis tündöklése és bukása. Ideggyogy Sz 2011;64:385-93.
6. Litvan I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86.
7. Rihmer Z, Gonda X, Döme P. Depression in Parkinson's disease. Ideggyogy Sz 2014;67:229-36.
8. Rascol O, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10:415-23.
9. Montgomery EB, Jr. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010;75:1943; author reply 4-5.
10. Horstink M, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006;13:1170-85.
11. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8.
12. Horstink M, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDSES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006;13:1186-202.
13. Trenkwalder C, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011;26:90-9.
14. Dusek P, et al. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol 2010;33:186-90.
15. Poletti M, Bonuccelli U. Impulse control disorders in Parkinson's disease: the role of personality and cognitive status. J Neurol 2012;259:2269-77.
16. Aschermann Z, Kovacs N, Komoly S. Folyamatos dopaminerg stimuláció Parkinson-kórban: Leheto″ségek 2013-ban. Ideggyogy Sz 2013;66:209-10.
17. Kovács N, et al. Mély agyi stimuláció: egy új perspektíva a mozgászavarok kezelésében. Lege Artis Medicinae 2009;19:119-26.
18. Deli G, et al. Dystonia kezelése mély agyi stimulációval: 40 eset tapasztalatainak összefoglalása. Ideggyogy Sz 2012;65:249-60.
19. Janszky J, Balás I, Kovács N. Mély agyi stimuláció szerepe az epilepszia kezelésében. Ideggyogy Sz 2011;64:317-20.
20. Ferreira JJ, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol 2013;20:5-15.
21. Deuschl G, Schade-Brittinger C, Agid Y. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013;368:2038.
22. Moro E, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010;25:578-86.
23. Meissner W, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-23.
24. Fehér G, et al. A kétoldali szubtalamikus stimuláció hatékonysága az antiparkinson gyógyszerelés változtatásának tükrében. Ideggyogy Sz 2010;63:314-9.
25. Deli G, et al. Korábban és hatékonyabban: a mély agyi stimuláció szerepe a munkaképesség mego″rzésében. Ideggyogy Sz 2014;67 közlésre elfogadva.
26. Takáts A, Nagy H, Radics P, Tóth A, Tamás G. Kezelési leheto″ségek a Parkinson-kór elo″rehaladott stádiumában. Ideggyogy Sz 2013;66:365-71.
27. Klivényi P, Vécsei L. Levodopa/carbidopa intestinalis géllel végzett klinikai vizsgálatok. Ideggyogy Sz 2014;67:5-8.
28. Kovács N, et al. Levodopa/carbidopa intestinalis gél kezelés hatása az életmino″ségre. Ideggyogy Sz 2014;67:245-50.
29. Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR. Physical therapy in Parkinson's disease: evolution and future challenges. Mov Disord 2009;24:1-14.
30. Keus SH, Bloem BR, Hendriks EJ, Bredero-Cohen AB, Munneke M. Evidence-based analysis of physical therapy in Parkinson's disease with recommendations for practice and research. Mov Disord 2007;22:451-60; quiz 600.
31. Tomlinson CL, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev 2013. 9:CD002817.
32. Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov Disord 2010;25:2311-7.
33. Goldman JG, et al. Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. Parkinsonism Relat Disord 2013;19:806-11.
34. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011;82:1033-7.
35. Kaszas B, et al. Sensitivity and specificity of Adden-brooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease. Parkinsonism Relat Disord 2012;18:553-6.
36. Volosin M, Janacsek K, Nemeth D. A Montreal Kognitiv Felmérés (MoCA) magyar nyelvu″ adaptálása egészséges, enyhe kognitiv zavarban és demenciában szenvedo″ ido″s személyek körében. Psychiatr Hung 2013;28:370-92.
37. Classen S. Consensus statements on driving in people with Parkinson's disease. Occup Ther Health Care 2014;28:140-7.